Total mesorectal excision and preoperative radiotherapy in mid and low rectal cancer allow us to achieve very good oncological results. However, major and refractory low anterior resection syndrome and fecal incontinence alter the quality of life of patients with a long expected life span.
We assessed the functional results of patients treated by antegrade enema for refractory low anterior resection syndrome and fecal incontinence after total mesorectal excision.
This is a prospective monocentric study from 2012 to 2016.
Patients who underwent percutaneous endoscopic cecostomy for refractory low anterior resection syndrome and fecal incontinence after total mesorectal excision were prospectively analyzed.
We assessed the morbidity of the procedure and compared low anterior resection syndrome score, Wexner score, and Gastrointestinal Quality of Life Index before and after the use of antegrade enema.
Of 25 patients treated by antegrade enema over the study period, 6 (24%) had a low anterior resection, 18 (72%) had a coloanal anastomosis, and 1 (4%) had a perineal colostomy. Postoperatively, the rate of local abscess was 8%, all treated by antibiotics. Low anterior resection syndrome score (33 vs 4, p < 0.001), Wexner score (16 vs 4, p <0.001), and Gastrointestinal Quality of Life Index (73 vs 104, p < 0.001) were all significantly improved after antegrade enema. The 2 main symptoms reported by patients were sweating (28%) and local pain (36%). At the end of the follow-up, 16% (n = 4) catheters were removed, and the rate of definitive colostomy was 12% (n = 3).
The main limitations of this study are the monocentric features and the sample size.
Antegrade enema for major and refractory low anterior resection syndrome and fecal incontinence after total mesorectal excision appears to be a promising treatment to avoid definitive colostomy. See Video Abstract at http://links.lww.com/DCR/A608.
1 CHU Bordeaux, Magellan Hospital, Department of Digestive Surgery, Pessac, France
2 University of Bordeaux Segalen, Bordeaux, France
3 CHU Bordeaux, Magellan Hospital, Department of Gastro-enterology, Pessac, France
4 University of Bordeaux, Bordeaux, France
Support/Funding: None reported.
Financial Disclosure: None reported.
Correspondence: Quentin Denost, M.D., Ph.D., Service de Chirurgie Digestive, Centre medico chirurgical Magellan, 33600 Pessac, France. E-mail: firstname.lastname@example.org